Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance

William R. Crom, Anne M. Glynn, Minnie Abromowitch, Ching‐Hon ‐H Pui, Richard Dodge, William E. Evans

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Systemic methotrexate (MTX) clearance was determined in 108 children who received 15 courses of MTX, 1000 mg/m2 iv over 24 hours, as a component of therapy for acute lymphocytic leukemia. The median MTX clearance was used as the representative value for each patient, and these values ranged from 44.7 to 132.1 ml/min/m2(X̄ = 78.4 ml/min/m2). The automatic interaction detector approach was used to determine the patient characteristics that correlated with MTX clearance. Characteristics examined were sex, age, estimated Creatinine clearance, SGPT, and body surface area. The initial splits were based on Creatinine clearance, and mean MTX clearances in three subgroups (50 to 100, 100 to 150, and >150 ml/min/m2) were 73.1, 78.3, and 90.5 ml/min/m2, respectively. For patients with the slowest Creatinine clearance, abnormal SGPT concentrations (>35 IU/L) were associated with slower MTX clearance (77.6 vs. 67.8 ml/min/m2). In the latter subgroup, boys had faster clearance than girls (77.4 vs. 60.9 ml/min/ m2). These results demonstrate that for children with normal serum Creatinine concentrations, interpatient variability in MTX clearance can partly be explained by measures of renal and hepatic function, which indicates that the observed variability in MTX clearance is not totally random. Clinical Pharmacology and Therapeutics (1986) 39, 592–597; doi:

Original languageEnglish (US)
Pages (from-to)592-597
Number of pages6
JournalClinical Pharmacology & Therapeutics
Volume39
Issue number5
DOIs
StatePublished - May 1986

Fingerprint

Methotrexate
Creatinine
Alanine Transaminase
Clinical Pharmacology
Body Surface Area
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Kidney
Liver
Therapeutics
Serum

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance. / Crom, William R.; Glynn, Anne M.; Abromowitch, Minnie; Pui, Ching‐Hon ‐H; Dodge, Richard; Evans, William E.

In: Clinical Pharmacology & Therapeutics, Vol. 39, No. 5, 05.1986, p. 592-597.

Research output: Contribution to journalArticle

Crom, William R. ; Glynn, Anne M. ; Abromowitch, Minnie ; Pui, Ching‐Hon ‐H ; Dodge, Richard ; Evans, William E. / Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance. In: Clinical Pharmacology & Therapeutics. 1986 ; Vol. 39, No. 5. pp. 592-597.
@article{b61093d4134e4140b3b777f3f7b23548,
title = "Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance",
abstract = "Systemic methotrexate (MTX) clearance was determined in 108 children who received 15 courses of MTX, 1000 mg/m2 iv over 24 hours, as a component of therapy for acute lymphocytic leukemia. The median MTX clearance was used as the representative value for each patient, and these values ranged from 44.7 to 132.1 ml/min/m2(X̄ = 78.4 ml/min/m2). The automatic interaction detector approach was used to determine the patient characteristics that correlated with MTX clearance. Characteristics examined were sex, age, estimated Creatinine clearance, SGPT, and body surface area. The initial splits were based on Creatinine clearance, and mean MTX clearances in three subgroups (50 to 100, 100 to 150, and >150 ml/min/m2) were 73.1, 78.3, and 90.5 ml/min/m2, respectively. For patients with the slowest Creatinine clearance, abnormal SGPT concentrations (>35 IU/L) were associated with slower MTX clearance (77.6 vs. 67.8 ml/min/m2). In the latter subgroup, boys had faster clearance than girls (77.4 vs. 60.9 ml/min/ m2). These results demonstrate that for children with normal serum Creatinine concentrations, interpatient variability in MTX clearance can partly be explained by measures of renal and hepatic function, which indicates that the observed variability in MTX clearance is not totally random. Clinical Pharmacology and Therapeutics (1986) 39, 592–597; doi:",
author = "Crom, {William R.} and Glynn, {Anne M.} and Minnie Abromowitch and Pui, {Ching‐Hon ‐H} and Richard Dodge and Evans, {William E.}",
year = "1986",
month = "5",
doi = "10.1038/clpt.1986.102",
language = "English (US)",
volume = "39",
pages = "592--597",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance

AU - Crom, William R.

AU - Glynn, Anne M.

AU - Abromowitch, Minnie

AU - Pui, Ching‐Hon ‐H

AU - Dodge, Richard

AU - Evans, William E.

PY - 1986/5

Y1 - 1986/5

N2 - Systemic methotrexate (MTX) clearance was determined in 108 children who received 15 courses of MTX, 1000 mg/m2 iv over 24 hours, as a component of therapy for acute lymphocytic leukemia. The median MTX clearance was used as the representative value for each patient, and these values ranged from 44.7 to 132.1 ml/min/m2(X̄ = 78.4 ml/min/m2). The automatic interaction detector approach was used to determine the patient characteristics that correlated with MTX clearance. Characteristics examined were sex, age, estimated Creatinine clearance, SGPT, and body surface area. The initial splits were based on Creatinine clearance, and mean MTX clearances in three subgroups (50 to 100, 100 to 150, and >150 ml/min/m2) were 73.1, 78.3, and 90.5 ml/min/m2, respectively. For patients with the slowest Creatinine clearance, abnormal SGPT concentrations (>35 IU/L) were associated with slower MTX clearance (77.6 vs. 67.8 ml/min/m2). In the latter subgroup, boys had faster clearance than girls (77.4 vs. 60.9 ml/min/ m2). These results demonstrate that for children with normal serum Creatinine concentrations, interpatient variability in MTX clearance can partly be explained by measures of renal and hepatic function, which indicates that the observed variability in MTX clearance is not totally random. Clinical Pharmacology and Therapeutics (1986) 39, 592–597; doi:

AB - Systemic methotrexate (MTX) clearance was determined in 108 children who received 15 courses of MTX, 1000 mg/m2 iv over 24 hours, as a component of therapy for acute lymphocytic leukemia. The median MTX clearance was used as the representative value for each patient, and these values ranged from 44.7 to 132.1 ml/min/m2(X̄ = 78.4 ml/min/m2). The automatic interaction detector approach was used to determine the patient characteristics that correlated with MTX clearance. Characteristics examined were sex, age, estimated Creatinine clearance, SGPT, and body surface area. The initial splits were based on Creatinine clearance, and mean MTX clearances in three subgroups (50 to 100, 100 to 150, and >150 ml/min/m2) were 73.1, 78.3, and 90.5 ml/min/m2, respectively. For patients with the slowest Creatinine clearance, abnormal SGPT concentrations (>35 IU/L) were associated with slower MTX clearance (77.6 vs. 67.8 ml/min/m2). In the latter subgroup, boys had faster clearance than girls (77.4 vs. 60.9 ml/min/ m2). These results demonstrate that for children with normal serum Creatinine concentrations, interpatient variability in MTX clearance can partly be explained by measures of renal and hepatic function, which indicates that the observed variability in MTX clearance is not totally random. Clinical Pharmacology and Therapeutics (1986) 39, 592–597; doi:

UR - http://www.scopus.com/inward/record.url?scp=0022590490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022590490&partnerID=8YFLogxK

U2 - 10.1038/clpt.1986.102

DO - 10.1038/clpt.1986.102

M3 - Article

C2 - 3516513

AN - SCOPUS:0022590490

VL - 39

SP - 592

EP - 597

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -